Background: Over the last two decades, the prevalence of colistin resistance among the members of has been increasing, particularly among isolates; this limits the potential use of colistin and leads to worsened clinical outcomes.
Methods: We investigated the prevalence and genetic characteristics of colistin-resistant (COLR-KP) in clinical isolates using genomic sequencing.
Results: In total, 53 K isolates (4.5%, 53/1,171) were confirmed as COLR-KP, of which eight isolates carried mobile colistin-resistant () gene. Although the overall prevalence rate (0.7%, 8/1,171) of -like genes in clinical remained relatively low, the presence of (15.1%, 8/53) among the COLR-KP isolates indicated that the mobile resistance gene was already widespread among isolates in hospital setting. We randomly selected 13 COLR-KP isolates (four -bearing and nine non--bearing isolates) for whole-genome sequencing, including two pandrug-resistant and four sequence type 11 (ST11) isolates. Phylogenetic analysis revealed that all COLR-KP isolates were genetically diverse. Among the four -bearing isolates, three (KP4, KP18, and KP30) were positive for and one (KP23) for ; none of the other genes were detected. The in the KP4 and KP30 isolates were located in an plasmid (approximately 33 kb) and could be successfully transferred to J53AZ. In contrast, for the -bearing plasmid in KP23 (), colistin resistance could not be transferred by conjugation. The mcr-1-producing isolate KP18 coexists a novel plasmid-carried tigecycline resistance gene tmexCD1-toprJ1. The most common chromosomal mutation associated with colistin resistance was a T246A amino acid substitution in PmrB, which was identified in most COLR-KP isolates (11/13, 84.6%). All ST11 isolates additionally had an R256G amino acid substitution. Critical virulence factors associated with hypervirulent were detected in four COLR-KP isolates; these virulence factors included aerobactin, salmochelin, and yersiniabactin.
Conclusion: We found that -bearing COLR-KP emerged in our hospital and was growing at an increasing rate. Simultaneous emergence of hypervirulence and colistin-tigecycline-carbapenem resistance in the epidemic clone ST11 was also observed; this highlights the significance of active and continuous surveillance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576191 | PMC |
http://dx.doi.org/10.3389/fcimb.2021.673503 | DOI Listing |
Chem Biol Drug Des
January 2024
Medical and Biological Computing Laboratory, School of Biosciences and Technology (SBST), Vellore Institute of Technology (VIT), Vellore, India.
Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections continue to impose high morbidity threats to hospitalized patients worldwide, limiting therapeutic options to last-resort antibiotics like colistin. However, the dynamic genomic landscape of colistin-resistant K. pneumoniae (COLR-Kp) invoked ardent exploration of underlying molecular signatures for therapeutic propositions/designs.
View Article and Find Full Text PDFPoult Sci
September 2022
College of Veterinary Medicine & Shandong Provincial Key Laboratory of Animal Biotechnology and Disease Control and Prevention, Shandong Agricultural University, Shandong, 271018, PR China. Electronic address:
Klebsiella pneumoniae (K. pneumoniae) is a conditionally pathogenic bacterium present in the intestinal or the respiratory tract of animals, and it is a common factor in acquired infections and a major threat to public health. Increased production of extended-spectrum β-lactamases (ESBLs) has become a serious issue in the treatment of K.
View Article and Find Full Text PDFFront Cell Infect Microbiol
November 2021
Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Int J Antimicrob Agents
December 2021
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address:
Concerns regarding carbapenem-resistant Klebsiella pneumoniae (CR-Kp), especially in bloodstream infections (BSIs), are continuing to increase worldwide. Several novel agents with activity against BSI CR-Kp have been approved or are in late-stage clinical development. In this study, the antibacterial effects of ceftazidime/avibactam (CZA), aztreonam/avibactam (AZA), meropenem/vaborbactam (MEV), imipenem-cilastatin/relebactam (ICR) and eravacycline (ERV) against three colistin-resistant CR-Kp (COLR-Kp) and four CZA-resistant CR-Kp (CZAR-Kp) were tested by time-kill assay.
View Article and Find Full Text PDFBiology (Basel)
May 2021
Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Koc University, Istanbul 34450, Turkey.
We proposed the hypothesis that high-risk clones of colistin-resistant (ColR-Kp) possesses a high number of virulence factors and has enhanced survival capacity against the neutrophil activity. We studied virulence genes of ColR-Kp isolates and neutrophil response in 142 patients with invasive ColR-Kp infections. The ST101 and ST395 ColR-Kp infections had higher 30-day mortality (58%, = 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!